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CLINICAL INVESTIGATION
Hyperphosphatemia in Pediatric Oncology Patients Receiving
Liposomal Amphotericin B
Chad A. Knoderer, PharmD1,2,3 and Holly M. Knoderer, MD, MS4
1Department of Pharmacy Practice, College of Pharmacy andHealth Sciences, Butler University, Indianapolis, Indiana;
2Department of Pharmacy, Riley Hospital for Children, Indiana University Health and Department of Pediatrics,
Indianapolis, Indiana; 3RyanWhite Center for Pediatric Infectious Disease, Indiana University School of Medicine,
Indianapolis, Indiana; 4Department of Pediatrics, Section ofPediatricHematology/Oncology, IndianaUniversity School
of Medicine, Indianapolis, Indiana
OBJECTIVE After transitioning our front-line amphotericin product to the liposomal formulation, we
observed an increased incidence of hyperphosphatemia. We aimed to determine the incidence of
hyperphosphatemia in children with oncologic disorders receiving an amphotericin B product and to
establish whether the incidence varies depending on amphotericin formulation.
METHODS This retrospective review of the medical record was conducted at a tertiary, free standing
children’s hospital. Pharmacy data revealed 159 patients receiving an amphotericin product between
November 2006 and December 2008. Doses of amphotericin, serum phosphorous, calcium and creatinine
concentrations were recorded at daily time points during the 10 days following both initiation and
discontinuation of amphotericin. Administration of phosphate binders and total parenteral nutrition was
noted. The incidence of hyperphosphatemia, defined as a serum value greater than the age-adjusted upper
limit of normal, was compared among the amphotericin groups.
RESULTS One hundred thirty-nine amphotericin recipients had a serum phosphorus measurement during
amphotericin therapy. Final analysis included 117 children, of which 64 (55%) were oncology patients.
Deoxycholate (mean maximum dose 1 mg/kg), lipid complex (mean maximum dose 4.8 mg/kg) and
liposomal amphotericin (mean maximum dose 4.9 mg/kg) were used in 24 (20.5%), 37 (31.6%) and 56
(47.9%) of all patients, respectively. Hyperphosphatemia developed in 27% (32/117) of all patients, and in
33% (21/64) of oncology patients. Similar to within all recipients, among oncology patients, 45% (n¼18)
of liposomal recipients demonstrated hyperphosphatemia compared to 13% of those receiving lipid
complex (n¼3, p¼0.007). No oncology patient received deoxycholate.
CONCLUSION Nearly 45% of children with oncologic disorders receiving liposomal amphotericin
developed hyperphosphatemia. The incidence is significantly greater for the liposomal formulation than
either of the other amphotericin formulations.
INDEX TERMS amphotericin, antifungal, electrolyte, hyperphosphatemia, pediatric oncology
ABBREVIATIONS ABLC, Abelcet; AMBD, amphotericin B deoxycholate; AMBL, AmBisome; CaXP, serum
calcium-phosphorus product
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BACKGROUND
Fungal infections are of particular concern in
immunocompromised patients, and greatly contrib-
ute to morbidity and mortality in children with
oncologic disorders. Amphotericin B is an antifun-
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gal agent with activity against many fungi subspe-
cies including Candida spp., Aspergillus spp. and
Cryptococcus species.1,2 Due to its wide spectrum
of activity, amphotericin B remains a mainstay of
antifungal treatment despite the extensive toxicity
proﬁle that limits its usefulness in certain patients.
Currently, a lipid formulation, either amphotericin
B lipid complex (Abelcet, Enzon, Bridgewater, NJ;
ABLC) or amphotericin B liposome (AmBisome,
Gilead Sciences, Foster City, CA; AMBL), is
preferred in oncology patients due to decreased
toxicity. The liposomal formulation is favored in
our institution.
Although not considered a common side effect
of ampotericin therapy, hyperphosphatemia has
been previously characterized in 5 children receiving
AMBL.3,4 Reports in adults have implicated
liposomal amphotericin as a cause of a pseudohy-
perphosphatemia. An interaction with the assay
equipment was hypothesized to result in a pseudo
rather than real phosphorous elevation.5–8 After
transitioning the amphotericin formulation at our
institution to AMBL, we observed more frequent
hyperphosphatemia. Our objective was to deter-
mine the incidence of hyperphosphatemia in chil-
dren with oncologic disorders receiving an
amphotericin B product and to establish whether
the incidence varies depending on amphotericin
formulation.
METHODS
This retrospective study was approved by the
institutional review board at Indiana University-
Purdue University, Indianapolis, Indiana. All pa-
tients, 18 years and younger, who received ampho-
tericin B deoxycholate (XGen Pharmaceuticals, Big
Flats, NY; AMBD), amphotericin B lipid complex
(ABLC), or liposomal amphotericin B (AMBL)
from November 2006 through December 2008 at
Riley Hospital for Children, Indianapolis, Indiana
were eligible for inclusion. Causes for exclusion
included: lack of baseline serum phosphorus
measurement, elevated baseline phosphorus, no
serum phosphorus measurement during the ﬁrst
10 days of amphotericin therapy and hyperphos-
phatemia with concomitant nephrotoxicity during
amphotericin therapy. Hyperphosphatemia was
deﬁned as a serum phosphorus concentration
greater than the age-adjusted upper limit of normal
at our institution. Nephrotoxicity was deﬁned as a
greater than 25% increase in two consecutive serum
creatinine concentrations from the baseline value.
Data collected included age, weight, gender and
baseline serum creatinine, calcium and phosphorus
concentrations. Information regarding amphoteri-
cin B included formulation, dose and duration of
therapy. Additionally, we documented administra-
tion of phosphate binder, phosphorus supplement,
and/or parenteral nutrition. Serum creatinine,
phosphorus and calcium values were recorded
during the ﬁrst 10 days following both initiation
and discontinuation of amphotericin therapy. The
serum calcium-phosphorus product was calculated
in hyperphosphatemic patents by multiplying the
serum calcium and phosphorus values.
Baseline characteristics were analyzed via re-
peated measures analysis of variance (ANOVA). A
Fisher’s exact analysis was be used to compare the
incidence of hyperphosphatemia treatment between
the three amphotericin groups. P-values of ,0.05
were considered statistically signiﬁcant. Statistical
analyses were conducted using Statistical Package
for Social Sciences version 16.0 (SPSS, Inc.,
Chicago). Data are presented as mean 6 standard
deviation.
RESULTS
Electronic pharmacy records revealed 159 chil-
dren who received an intravenous (IV) amphoter-
icin product during the study period. Of these, 139
had a phosphorus measurement during amphoter-
icin therapy and 117 were included in ﬁnal analysis.
Additional exclusions were for age (n¼10), no
baseline phosphorus measurement (n¼2), elevated
baseline phosphorus (n¼4), and concomitant neph-
rotoxicity (n¼6). Sixty-four (55%) were patients
being treated for oncologic disorders with a mean
age of 88.3 6 63.5 months and weight of 26 6 18
kg. Forty-eight percent of oncology patients were
male. Table 1 illustrates amphotericin formulation
distribution.
Hyperphosphatemia developed in 27% (32/117)
of all amphotericin recipients. The incidence among
the oncology (33%, n¼21) and nononcology (21%,
n¼11) population was similar (p¼0.145). Among
oncology patients, hyperphosphatemia developed
more frequently in recipients of AMBL (45%) than
in those treated with ABLC (13%; p¼0.007). No
oncology patient received AMBD. This difference
in hyperphosphatemia was not observed outside of
the oncology population (Table 2).
Hyperphosphatemia after AMBL was similar
among oncology (45%) and nononcology patients
(37.5%; p¼0.608). The incidence of hyperphospha-
temia was not different in those receiving total
parenteral nutrition and nonrecipients (p¼0.948).
No patient received supplemental phosphorus.
There was no difference in the doses (mg/kg) of
ABLC (4.85 6 0.61 and 4.62 6 1; p¼0.444) or
AMBL (4.95 6 0.81 and 4.87 6 1.4; p¼0.789) in
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patients with and without hyperphosphatemia,
respectively. Table 3 describes mean phosphorus
values in oncology patients with hyperphosphos-
phatemia and the mean percent above the age-
adjusted upper limit of normal.
A similar proportion of the AMBL (42%) and
ABLC (50%) recipients under 12 years of age
developed a serum calcium-phosphorus product
(CaXP) greater than 65 mg2/dL2 (p¼NS). For
patients older than 12 years of age, a serum CaXP
greater than 55 mg2/dL2 was observed in 60% of
AMBL recipients, but was not noted in the ABLC
recipients. The median (range) percent change in
serum calcium for patients with hyperphosphatemia
was zero (21.43% to 43.02%).
The mean delay between amphotericin initiation
and hyperphosphatemia onset was 4.1 6 2.2 days
(range: 1–9). Resolution of hyperphosphatemia
occurred within 10 days of amphotericin discontin-
uation in 11 (61%) AMBL and 2 (67%) ABLC
recipients. No patient required phosphate binders
or other intervention to decrease phosphorus
concentrations.
DISCUSSION
Pediatric oncology patients experience electro-
lyte abnormalities for varied reasons and prompt
recognition can be critical. Based on observational
experiences, we aimed to determine if different
liposomal amphotericin formulations were associ-
ated with differing rates of hyperphosphatemia. We
found that nearly 45% of children with oncologic
disorders developed hyperphosphatemia during
AMBL therapy. Hyperphosphatemia incidence is
signiﬁcantly higher with the liposomal formulation
than the other available formulations.
Hyperphosphatemia is a common problem in
those with kidney disease, and is a manifestation of
tumor lysis syndrome. However, little has been
reported about any signiﬁcance of hyperphospha-
temia in pediatric cancer patients without renal
insufﬁciency. Severe hyperphosphatemia can con-
tribute to rhabdomyolysis, hemolysis, decreased
oxygen transport and respiratory failure in those
with chronic kidney disease.9,10
Table 1. Amphotericin formulation distribution among
all patients
Formulation
Number
(%) of
Recipients
Median
(Range)
Age in
Months
Mean Max
Dose
(mg/kg)
AMBD 24 (20.5%) 1 (1–197) 1
ABLC 37 (31.6%) 47 (2–215) 4.8
AMBL 56 (47.9%) 68 (1–213) 4.9
ABLC, amphotericin B lipid complex; AMBD, amphotericin B
deoxycholate; AMBL, liposomal amphotericin B
Table 2. Hyperphosphatemia incidence among ampho-
tericin formulations
Formulation Patients (%)
Nononcology patients (n¼53) *
AMBD (n¼24) 2 (8.3%)
ABLC (n¼13) 3 (23.1%)
AMBL (n¼16) 6 (37.5%)
Oncology patients (n¼64) †
ABLC (n¼24) 3 (13%)
AMBL (n¼40) 18 (45%)
ABLC, amphotericin B lipid complex; AMBD, amphotericin B
deoxycholate; AMBL, liposomal amphotericin B
* p¼0.042 for AMBD vs. AMBL and p¼0.454 for ABLC vs. AMBL
† p¼ 0.007 for ABLC vs. AMBL
Table 3. Phosphorus concentrations in patients with
hyperphosphatemia
Amphotericin
Formulation
Upper
Limit of
Normal*
Mean
Highest
Phosphorus
(mg/dL)
Mean
Percent
Above Upper
Limit of
Normal^
ABLC 5.2 (n¼1) 5.8 11.5%
5.5 (n¼1) 5.9 7.3%
6.5 (n¼1) 6.8 4.6%
Total (n¼3) 6.2 7.8%
AMBL 5.2 (n¼6) 6.2 18.6%
5.5 (n¼7) 6.2 12.7%
6.5 (n¼3) 7.7 19%
6.8 (n¼2) 7.2 5.9%
Total (n¼18) 6.9 18.3%
ABLC, amphotericin B lipid complex; AMBL, amphotericin B
liposome; ULN, upper limits of normal
* upper limits of normal serum phosphorus based on age: 4 mo-1
yr ¼ 6.8 mg/dL; 1–5 yrs ¼ 6.5 mg/dL; 5-10 yrs ¼ 5.5 mg/dL; and
10–20 yrs ¼ 5.2 mg/dL
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Importantly, excess serum phosphorus binds
calcium in the body and vasculature. A serum
CaXP greater than 55 mg2/dL2 results in soft tissue
and cardiovascular calciﬁcation increasing both
morbidity and mortality.9 The National Kidney
Foundation Kidney Disease Outcomes Quality
Initiative recommends that serum CaXP be main-
tained less than 55 mg2/dL2 in those over 12 years
of age and less than 65 mg2/dL2 in younger
children.11 It is both impressive and concerning
that 47% of our AMBL recipients had a calcium-
phosphorus product in excess of these recommen-
dations. Mean peak phosphorus values ranged from
6% – 19% above the upper limit of normal for
oncology AMBL recipients. How this elevation
affects the calcium-phosphorus product and subse-
quent alteration in morbidity and mortality war-
rants investigation.
Hyperphosphatemia due to AMBL has been
previously described in 5 children (age 8 – 18
years).3,4 Four reports included children with
malignancy. In all cases, hyperphosphatemia was
observed after initiation of AMBL. These eleva-
tions were observed as early as 1 day after initiation
of AMBL. In 1 child, hyperphosphatemia occurred
intermittently throughout a month of amphotericin
therapy.4 Our ﬁndings are similar in that hyper-
phosphatemia onset occurred between 1 and 9 days
after initiation of AMBL.
Sutherland and colleagues note the use of the
Synchron LX-20 (Beckman Coulter Inc., Brea, CA)
analysis method.4 Case reports of 6 adults and
laboratory studies have implicated AMBL as an
etiology of pseudohyperphosphatemia due to an
interaction between the AMBL and the Synchron
LX-20 method.5–8 It has been proposed that
elevated phosphorus may be due to degradation
of the liposomal vehicle of AMBL causing inter-
ference with Synchron LX-20.6 Within our institu-
tion, serum phosphorus is measured using a
different apparatus, the Synchron DxC (Beckman
Coulter) system, which leads to question if the
hyperphosphatemia is real or if this is a machine
interaction with the Synchron systems. It is
important to note that despite a phosphorous
elevation, there was no signiﬁcant reduction in
serum calcium concentration. Such a decline would
have supported true hyperphosphatemia over pseu-
dohyperphosphatemia. We did not aim to deter-
mine if the hyperphosphatemia we observed after
transitioning to AMBL was a pseudohyperphos-
phatemia, rather we simply wished to characterize
the incidence of hyperphosphatemia among am-
photericin formulations. Future investigation to
determine true versus pseudohyperphosphatemia is
warranted. Clinicians should be aware of this
potential phosphorus elevation and the institution-
al-analysis methods used while carefully evaluating
the patient clinical status in order to avoid
inappropriate interventions aimed at hyperphos-
phatemia treatment.
A limitation to this study is that it was a
retrospective chart review. Although all included
patients had at least one phosphorus value drawn
during amphotericin B therapy, not all patients had
daily measurements. While 45% of our AMBL
recipients developed hyperphosphatemia, 13% of
our ABLC patients developed this as well. This
difference was not observed in the nononcology
population. A larger sample size may have yielded
additional ﬁndings given the relative infrequent use
of ABLC use in our oncology population.
CONCLUSION
Nearly 45% of children with oncologic disorders
developed hyperphosphatemia while receiving ther-
apy with AMBL. The incidence of hyperphospha-
temia is higher with the liposomal formulation than
the other available formulations. Clinicians should
be aware of this and the analytical method used
within their institution to optimally manage pa-
tients with hyperphosphatemia. Our ﬁndings repre-
sent important potential adverse data that is often
difﬁcult to ascertain through voluntary post-mar-
keting reporting. Further investigation is warranted
to determine the signiﬁcance of this ﬁnding and
whether it represents a true or pseudohyperphos-
phatemia.
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